From TekinHealthHealthcare Tech Field Notes

Precision Neuroscience closed an oversubscribed $250 million Series D led by Pershing Square, the Ackman Oxman Institute and an undisclosed life-sciences investment fund, bringing its total raised since founding in 2021 to $430 million. Its Layer 7 Cortical Interface, a thin-film array of 1,024 electrodes that sits on the brain's surface without penetrating tissue, received FDA 510(k) clearance in 2025 for implantation up to 30 days. The company says it has completed more than 100 patient procedures across 18 medical institutions, including Mount Sinai, University of Chicago Medicine and Penn, and has a commercial partnership with Medtronic. Precision says the new funding will expand its clinical program and support further FDA review.

Why it's notable: It's one of the largest rounds yet for a brain-computer interface company, and one of the few with an FDA-cleared implant already in hospital use rather than confined to research settings, signaling BCI is moving from experimental to clinical faster than expected.

Melbourne-based Heidi Health raised $340 million: a $100 million Series C led by Blackbird at a $900 million valuation, plus $240 million in growth investment from General Catalyst. The company says its tools support 2.8 million patient visits a week in 190 countries. Its customers include Beth Israel Lahey Health and NHS England Midlands, which Heidi calls the largest clinical AI procurement in NHS history. Heidi plans to move from documentation into supervised, agent-style tasks it calls an AI Care Partner.

Why it's notable: This is one of the largest rounds yet for an ambient-scribe company outside the US leaders. It shows scribe vendors racing to take on more clinical and administrative work, which clinics will see in upcoming product and pricing choices.

Sword Health, a virtual physical therapy company, plans to acquire Headspace's parent company OrangeDot for cash. The deal became public on August 25, 2026, through a filing with the Massachusetts Health Policy Commission. The filing did not give a price. Axios reported the deal at up to about $300 million, far below the roughly $3 billion Headspace was valued at after its 2021 merger with Ginger. Headspace offers therapy, coaching and meditation content and says its app has reached more than 100 million people. Sword formally announced the deal on September 16 and said it expects it to close by early in the fourth quarter.

Why it's notable: A former digital mental health leader is being sold at a fraction of its peak value to an AI-driven virtual care company. The deal shows the category consolidating, and it brings mental health support into the same platform employers already buy for musculoskeletal care.

Tempus AI agreed on July 20, 2026 to acquire Personalis for $16.25 per share, valuing the deal at about $1.5 billion. The deal adds Personalis's NeXT Personal minimal residual disease (MRD) blood test, which Tempus has sold under a partnership since 2023, to its AI-driven precision oncology platform. The deal is mainly in stock, with Tempus able to pay up to half in cash. It needs Personalis shareholder and regulatory approval and is expected to close in late 2026 or early 2027.

Why it's notable: MRD testing, which tracks cancer recurrence from blood, is becoming part of routine oncology follow-up. The deal puts one of the more sensitive tests on the market under a large AI and genomic data company that oncologists already order from.

Assort Health raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, announced June 24, 2026, bringing its total funding to more than $222 million. Its voice and text agents answer patient calls and handle scheduling, triage, referrals, intake forms, refills, eligibility checks and payments, and they write encounter details back to the EHR. The company says revenue grew 20-fold over 15 months and that John Muir Health saw a 5% absolute increase in net appointment volume after deploying it.

Why it's notable: AI agents answering the front-desk phone are becoming one of the fastest-growing uses of AI in clinics and specialty practices, and they directly affect access, no-shows and staffing.

Cadence, which runs remote monitoring programs for hypertension, diabetes and heart failure with health systems, raised a $100 million Series C led by Spark Capital at a $1.23 billion valuation, announced June 23, 2026. The company says it works with more than 20 health systems and cares for over 100,000 active patients using home devices such as blood pressure cuffs and its own clinicians. Health systems including Corewell Health, Memorial Hermann and Duke Health invested in the round. CEO Chris Altchek told STAT the company plans to use AI agents to automate clinician work and is talking with the FDA about using agents in its hypertension program.

Why it's notable: It is one of the largest bets on outsourced remote monitoring for health systems. It comes as regulators and insurers such as UnitedHealthcare question whether monthly Medicare remote monitoring payments deliver real care.

Roche signed a definitive agreement on May 7, 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestone payments. PathAI makes AI models that analyze patient tissue samples and software for running digital pathology labs; Labcorp had expanded its use of the platform across its anatomic pathology labs earlier in 2026. The two companies had worked together since 2021, including on AI-based companion diagnostics. Roche said PathAI would join its Diagnostics division, with closing expected in the second half of 2026 pending antitrust and regulatory approval.

Why it's notable: One of the largest diagnostics companies is buying an AI pathology platform outright rather than partnering, a sign that AI-assisted slide review is moving into the standard lab product line that hospitals and reference labs buy.

On April 23, 2026, IKS Health agreed to acquire TruBridge for $26.25 a share in cash, a deal Fierce Healthcare valued at $557M including debt. TruBridge sells EHR, revenue cycle and coding services to more than 1,500 mostly rural and community hospitals and clinics. The companies say the combined business will serve more than 2,000 healthcare organizations and 150,000 clinicians. The deal closed on July 9, 2026, and existing TruBridge products remain available on their own.

Why it's notable: Many small rural hospitals rely on TruBridge for both their EHR and their billing. Its new owner plans to layer AI-driven revenue cycle services on top.

Hospital operator Universal Health Services (UHS) agreed on March 9, 2026 to acquire virtual behavioral health company Talkspace for $5.25 a share, an enterprise value of about $835 million. Talkspace brings about 6,000 licensed clinicians. It says it reaches more than 200 million Americans through employer and health plan contracts. UHS says the deal gives it inpatient, outpatient and virtual mental health care in one company. It expects Talkspace to add about $280 million in revenue. The deal closed on August 18, 2026.

Why it's notable: One of the largest US behavioral hospital operators is buying a national telehealth therapy network. Virtual therapy becomes a referral path into and out of its facilities, as mental health staffing shortages limit in-person capacity.

Imaging center operator RadNet said on March 2, 2026 that it is acquiring Paris-based Gleamer for up to €230 million in cash: €215 million upfront plus €15 million in milestones. Gleamer will be folded into RadNet's DeepHealth AI unit. Gleamer has four FDA-cleared products, including BoneView for fracture detection on X-rays, CT lung nodule detection and MRI multiple sclerosis lesion detection. It is forecast to reach about $30 million in annual recurring revenue in 2026. RadNet says the deal makes DeepHealth the largest radiology clinical AI provider worldwide.

Why it's notable: Radiology AI is consolidating. Hospitals and imaging groups buying point tools for X-ray, CT and MRI may increasingly buy them from one platform owned by a large imaging provider.

On February 17, 2026, Danaher agreed to buy Masimo for $180 a share in cash, an enterprise value of about $9.9 billion. Masimo makes pulse oximetry and patient-monitoring equipment used mainly in hospitals. It will run as a standalone business in Danaher's diagnostics segment, next to Radiometer, Cepheid, Beckman Coulter and Leica Biosystems. Danaher says it expects more than $125 million a year in cost savings and more than $50 million a year in added sales from the combination by the fifth year. The deal closed on June 10, 2026.

Why it's notable: A monitoring brand found at most hospital bedsides now belongs to one of the largest diagnostics companies. This sets Danaher up to compete directly with Medtronic in pulse oximetry and may change how hospitals buy monitors and blood-gas equipment together.

On January 15, 2026, Boston Scientific agreed to buy Penumbra for $374 a share in cash and stock, valuing the company at about $14.5 billion. About $11 billion of the price is cash, funded from cash on hand and new debt. Penumbra makes mechanical thrombectomy systems that remove clots in stroke, pulmonary embolism and deep vein thrombosis, along with embolization devices. Boston Scientific says it will run Penumbra as a standalone business inside its cardiovascular group. The FTC issued a second request for more information in March 2026, Penumbra stockholders approved the deal in May, and as of July Boston Scientific still expected it to close in the second half of 2026.

Why it's notable: It is one of the largest medtech deals in years, and it puts a leading maker of stroke and clot-removal devices inside one of the biggest cardiovascular device companies, which could change how hospitals contract for these devices.

On December 5, 2025, Freenome agreed to merge with Perceptive Capital Solutions Corp, a special purpose acquisition company (SPAC). The deal was expected to bring in about $330 million, including a $240 million private investment led by Perceptive Advisors and RA Capital. Freenome's SimpleScreen blood test for colorectal cancer was under FDA review, with a decision expected in mid-2026. Exact Sciences paid $75 million up front in August 2025 for US rights to the test, and Roche holds rights outside the US. The merger closed on July 20, 2026, with about $310 million in gross proceeds, and Freenome began trading on Nasdaq as FRNM.

Why it's notable: Blood-based colorectal cancer screening could reach patients who skip colonoscopy and stool tests. This deal funds one of the main contenders as it heads toward an FDA decision and a US launch through Exact Sciences.

Abbott agreed to acquire Exact Sciences for $105 a share in cash, an equity value of about $21 billion and roughly $23 billion including debt. Exact Sciences makes the Cologuard at-home colorectal cancer screening test, the Oncotype DX breast cancer test, and liquid biopsy tests for multi-cancer early detection and molecular residual disease. Abbott said Exact would bring in more than $3 billion in revenue in 2025 and raise Abbott's diagnostics sales above $12 billion a year. The deal closed on March 23, 2026.

Why it's notable: One of the largest diagnostics makers now owns the most widely used at-home colon cancer screening test and a set of newer blood-based cancer tests. That could affect how these tests are sold to clinics and paid for.

GE HealthCare agreed to acquire Intelerad, a Montreal-based maker of cloud PACS, image-sharing and imaging workflow software, for $2.3 billion in cash. Intelerad's business is concentrated in outpatient and ambulatory imaging. GE HealthCare expects about $270 million in Intelerad revenue in the first full year, roughly 90% of it recurring. GE HealthCare said the deal supports its goal of tripling its cloud-enabled products by 2028. The acquisition closed in March 2026.

Why it's notable: A major scanner maker is buying its way into cloud imaging software for outpatient imaging centers and specialty clinics. That will affect which PACS and imaging AI tools those sites get offered.

Hippocratic AI raised a $126 million Series C led by Avenir Growth at a $3.5 billion valuation. CapitalG, General Catalyst, Universal Health Services, Cincinnati Children's and WellSpan Health also took part. The company builds AI agents that talk with patients about scheduling, intake, chronic disease check-ins and post-discharge follow-up, and it does not let them diagnose or prescribe. It says it works with more than 50 health systems, payers and pharma companies in six countries, including Cleveland Clinic, Northwestern Medicine and Moffitt Cancer Center, and plans to use the money partly for acquisitions.

Why it's notable: Health systems are putting AI agents to work on routine patient phone and message outreach that staff used to handle. Investors are betting that this non-diagnostic work will scale first.

OpenEvidence, an AI medical reference tool for clinicians, raised $200 million at a $6 billion valuation in a round led by Google Ventures, with Sequoia, Kleiner Perkins, Blackstone, Thrive, Coatue, Bond and Craft participating. The round came three months after a $210 million raise at a $3.5 billion valuation. The company says monthly clinical consultations nearly doubled to about 15 million since July. The tool is free for verified clinicians and paid for by advertising, and it draws on journals including JAMA and NEJM.

Why it's notable: OpenEvidence has become one of the most widely used generative AI tools among U.S. clinicians, and its ad-supported free model sets it apart from AI products that health systems license.